Bosentan |
Tracleer |
Article: Bosentan
| Image:Bosentan.png | |
| Bosentan | |
| Systematic (IUPAC) name | |
| N-[6-(2-hydroxyethoxy)-5- (2-methoxyphenoxy) -2-pyrimidin-2-yl-pyrimidin-4-yl] -4-tert- butyl-benzenesulfonamide | |
| Identifiers | |
| CAS number | 147536-97-8 |
| ATC code | C02KX01 |
| PubChem | 104865 |
| DrugBank | APRD00829 |
| Chemical data | |
| Formula | C27H29N5O6S |
| Mol. weight | 551.615 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It's trade name is Tracleer®, which is an oral medication licensed in the U.S., European Union and other countries for the management of PAH. The license holder is Actelion Pharmaceuticals.
Categories: Medical treatment stubs | Endothelin receptor antagonists

Not Signed In -

